Taro Kishi

List of Publications by Year in Descending Order

154 papers	3,154 citations	32 h-index	48 g-index
159 ext. papers	3,671 ext. citations	4.7 avg, IF	5.44 L-index

#	Paper	IF	Citations
154	Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.. *Schizophrenia Research*, **2022**, 240, 231-232	3.6	1
153	Volume of Amygdala Subregions and Plasma Levels of Brain-Derived Neurotrophic Factor and Cortisol in Patients with s/s Genotype of Serotonin Transporter Gene Polymorphism of First-Episode and Drug-Naive Major Depressive Disorder: An Exploratory Study.. *Neurology International*, **2022**, 14, 378-390	1.2	
152	Early Improvement as a Predictor of Later Response to Lurasidone in Schizophrenia from Japan Trials: A Diagnostic Test.. *Psychiatry and Clinical Neurosciences*, **2022**,	6.2	0
151	Observations on the results of a systematic review and network meta-analysis of double-blind randomized, placebo-controlled trials to examine early onset of response to pharmacological intervention for bipolar depression. *Bipolar Disorders*, **2021**,	3.8	
150	Recurrence rates in stable bipolar disorder patients after drug discontinuation drug maintenance: a systematic review and meta-analysis. *Psychological Medicine*, **2021**, 51, 2721-2729	6.9	8
149	Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. *Molecular Psychiatry*, **2021**, 26, 4146-4157	15.1	17
148	Melatonin receptor agonists for bipolar mania: A systematic review and meta-analyses of double-blind randomized placebo-controlled trials. *Bipolar Disorders*, **2021**, 23, 301-302	3.8	2
147	Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. *Journal of Psychiatric Research*, **2021**, 138, 444-452	5.2	4
146	Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia. *Psychiatry and Clinical Neurosciences*, **2021**, 75, 240	6.2	1
145	Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia. *Journal of Psychiatric Research*, **2021**, 132, 144-150	5.2	1
144	Body composition in Japanese patients with psychiatric disorders: A cross-sectional study. *Neuropsychopharmacology Reports*, **2021**, 41, 117-121	2.2	2
143	Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. *Bipolar Disorders*, **2021**	3.8	2
142	Recurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis - Corrigendum. *Psychological Medicine*, **2021**, 51, 2730	6.9	1
141	Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. *Bipolar Disorders*, **2021**, 23, 730-731	3.8	0
140	Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. *Neuropsychopharmacology Reports*, **2021**, 41, 422-425	2.2	2
139	Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis. *Psychopharmacology*, **2021**, 238, 3585-3593	4.7	
138	Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. *Neuropsychopharmacology Reports*, **2021**,	2.2	2

137	Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. *Journal of Psychiatric Research*, **2020**, 128, 68-74	5.2	26
136	Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. *Psychiatry and Clinical Neurosciences*, **2020**, 74, 330-332	6.2	
135	Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. *Pharmacopsychiatry*, **2020**, 53, 122-132	2	2
134	Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. *Psychopharmacology*, **2020**, 237, 1459-1470	4.7	10
133	Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study. *Neuropsychiatric Disease and Treatment*, **2020**, 16, 2569-2577	3.1	1
132	Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. *Neuropsychopharmacology Reports*, **2020**, 40, 314-322	2.2	4
131	N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. *Psychopharmacology*, **2020**, 237, 3481-3487	4.7	11
130	Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis: Discontinuation in antipsychotic trials. *Journal of Psychiatric Research*, **2020**, 130, 240-246	5.2	1
129	Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. *Neuropsychopharmacology Reports*, **2020**, 40, 417-422	2.2	1
128	Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 2655-2661	3.1	3
127	Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2019**, 115, 121-128	5.2	3
126	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. *Neuropsychopharmacology Reports*, **2019**, 39, 241-246	2.2	6
125	Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. *Psychological Medicine*, **2019**, 49, 772-779	6.9	18
124	Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. *Neuropsychopharmacology Reports*, **2019**, 39, 256-259	2.2	2
123	Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study. *Neuropsychopharmacology Reports*, **2019**, 39, 252-255	2.2	3
122	COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 1537-1545	3.1	5
121	Melatonin receptor agonists-ramelteon and melatonin-for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 1479-1486	3.1	10
120	A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 2425-2432	3.1	2

119	Genetic effects on white matter integrity in drug-naive patients with major depressive disorder: a diffusion tensor imaging study of 17 genetic loci associated with depressive symptoms. *Neuropsychiatric Disease and Treatment*, **2019**, 15, 375-383	3.1	24
118	Response to the Letter from Dr. Jacob Peedicayil. *Psychopharmacology*, **2019**, 236, 1403-1404	4.7	
117	Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Pharmacopsychiatry*, **2019**, 52, 52-62	2	16
116	Response to the letter from Dr. Kim and colleagues. *Psychiatry Research*, **2018**, 263, 291-292	9.9	
115	Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study. *Frontiers in Psychiatry*, **2018**, 9, 52	5	6
114	Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. *Journal of Alzheimer's Disease*, **2018**, 64, 43-48	4.3	7
113	Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis. *Psychiatry Research*, **2018**, 260, 41-47	9.9	10
112	Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2018**, 14, 2915-2922	3.1	3
111	Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. *Neuropsychiatric Disease and Treatment*, **2018**, 14, 2519-2530	3.1	6
110	The efficacy and safety of memantine for the treatment of Alzheimer's disease. *Expert Opinion on Drug Safety*, **2018**, 17, 1053-1061	4.1	33
109	Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. *Psychopharmacology*, **2018**, 235, 2303-2314	4.7	19
108	Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. *International Journal of Neuropsychopharmacology*, **2018**, 21, 748-757	5.8	9
107	Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2017**, 267, 149-161	5.1	4
106	A Meta-Analysis of Memantine for Depression. *Journal of Alzheimer's Disease*, **2017**, 57, 113-121	4.3	29
105	Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. *Psychopharmacology*, **2017**, 234, 2113-2125	4.7	28
104	Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance. *Evidence-Based Mental Health*, **2017**, 20, 61	11.1	
103	Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. *Journal of Alzheimer's Disease*, **2017**, 60, 401-425	4.3	108
102	Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. *Neuropsychiatric Disease and Treatment*, **2017**, 13, 1281-1302	3.1	10

101	Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses. *Frontiers in Psychiatry*, **2017**, 8, 308	5	94
100	Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR. *Scientific Reports*, **2017**, 7, 3931	4.9	14
99	Response to the letter from Dr. Veerman and colleagues. *Psychopharmacology*, **2017**, 234, 3537-3538	4.7	
98	Z-drug for schizophrenia: A systematic review and meta-analysis. *Psychiatry Research*, **2017**, 256, 365-370	9.9	8
97	The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. *Neuropsychiatric Disease and Treatment*, **2017**, 13, 1909-1928	3.1	28
96	Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 767-74	5.5	62
95	Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2016**, 266, 439-50	5.1	33
94	Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials. *Journal of Alzheimer's Disease*, **2016**, 54, 635-43	4.3	26
93	Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. *Psychiatry Research*, **2016**, 246, 750-755	9.9	30
92	Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis. *Evidence-Based Mental Health*, **2016**, 19, 61	11.1	
91	Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	41
90	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. *Neuropsychiatric Disease and Treatment*, **2016**, 12, 3041-3049	3.1	7
89	Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Neuropsychiatric Disease and Treatment*, **2016**, 12, 3221-3236	3.1	10
88	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. *PLoS ONE*, **2016**, 11, e0150712	3.7	14
87	Routine use of antipsychotics to prevent or treat delirium is not recommended. *Evidence-Based Mental Health*, **2016**, 19, 123	11.1	
86	Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials. *Schizophrenia Bulletin*, **2016**, 42, 1438-1445	1.3	28
85	Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. *European Archives of Psychiatry and Clinical Neuroscience*, **2015**, 265, 259-68	5.1	32
84	A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia. *Comprehensive Psychiatry*, **2015**, 59, 91-7	7.3	11

83	Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials. *Journal of Psychiatric Research*, **2015**, 68, 198-209	5.2	38
82	Memantine for Lewy body disorders: systematic review and meta-analysis. *American Journal of Geriatric Psychiatry*, **2015**, 23, 373-383	6.5	20
81	Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. *International Journal of Neuropsychopharmacology*, **2015**, 19,	5.8	27
80	Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. *Neuropsychiatric Disease and Treatment*, **2015**, 11, 419-34	3.1	7
79	Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. *PLoS ONE* , **2015**, 10, e0123289	3.7	125
78	Relationship between a BDNF gene polymorphism and the brain volume in treatment-naive patients with major depressive disorder: A VBM analysis of brain MRI. *Psychiatry Research - Neuroimaging*, **2015**, 233, 120-4	2.9	37
77	Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *PLoS ONE*, **2015**, 10, e0136910	3.7	49
76	Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series. *Clinical Psychopharmacology and Neuroscience*, **2015**, 13, 109-12	3.4	11
75	Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *International Journal of Neuropsychopharmacology*, **2014**, 18,	5.8	55
74	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. *Psychiatry Research*, **2014**, 215, 803-5	9.9	1
73	Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. *International Journal of Neuropsychopharmacology*, **2014**, 17, 343-54	5.8	19
72	P4-193: COMBINATION THERAPY WITH CHOLINESTERASE INHIBITORS AND MEMANTINE FOR ALZHEIMER'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS **2014**, 10, P859-P860		14
71	Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE*, **2014**, 9, e88049	3.7	15
70	Early prediction of blonanserin response in Japanese patients with schizophrenia. *Neuropsychiatric Disease and Treatment*, **2014**, 10, 1861-6	3.1	4
69	The position of blonanserin as a treatment for schizophrenia. *Asia-Pacific Psychiatry*, **2014**, 6, 462	3.2	2
68	A meta-analysis of inositol for depression and anxiety disorders. *Human Psychopharmacology*, **2014**, 29, 55-63	2.3	42
67	Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Human Psychopharmacology*, **2014**, 29, 483-91	2.3	47
66	COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study. *Neuropsychiatric Disease and Treatment*, **2014**, 10, 1183-90	3.1	15

65	Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. *Annals of General Psychiatry*, **2014**, 13, 19	3.4	20
64	Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. *NeuroMolecular Medicine*, **2014**, 16, 61-9	4.6	23
63	Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. *European Archives of Psychiatry and Clinical Neuroscience*, **2013**, 263, 633-41	5.1	13
62	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. *European Archives of Psychiatry and Clinical Neuroscience*, **2013**, 263, 105-18	5.1	76
61	Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. *Asian Journal of Psychiatry*, **2013**, 6, 200-7	6.7	14
60	Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *CNS Drugs*, **2013**, 27, 731-41	6.7	13
59	Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 149-54	5.2	44
58	Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. *Human Psychopharmacology*, **2013**, 28, 80-6	2.3	71
57	Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 2018-20	5.2	20
56	NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 1143-9	5.2	45
55	Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. *Journal of Psychiatric Research*, **2013**, 47, 1557-63	5.2	10
54	Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. *Asian Journal of Psychiatry*, **2013**, 6, 86-7	6.7	4
53	Further evidence of an association between a genetic variant in BMP7 and treatment response to SSRIs in major depressive disorder. *Journal of Human Genetics*, **2013**, 58, 568-9	4.3	1
52	Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. *International Journal of Neuropsychopharmacology*, **2013**, 16, 1259-66	5.8	23
51	Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle reponses in Japanese patients with schizophrenia. *Human Psychopharmacology*, **2013**, 28, 220-9	2.3	4
50	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder. *Neuropsychiatric Disease and Treatment*, **2013**, 9, 781-6	3.1	4
49	Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis. *Human Psychopharmacology*, **2012**, 27, 63-9	2.3	6
48	GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. *Journal of Affective Disorders*, **2012**, 142, 315-22	6.6	8

47	Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis. *BMC Medical Genetics*, **2012**, 13, 76	2.1	27
46	The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia. *NeuroMolecular Medicine*, **2012**, 14, 131-8	4.6	9
45	Genome-wide association study of schizophrenia in a Japanese population. *Biological Psychiatry*, **2011**, 69, 472-8	7.9	145
44	The CLOCK gene and mood disorders: a case-control study and meta-analysis. *Chronobiology International*, **2011**, 28, 825-33	3.6	33
43	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. *Drug and Alcohol Dependence*, **2011**, 113, 1-7	4.9	11
42	Lack of association between translin-associated factor X gene (TSNAX) and methamphetamine dependence in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2011**, 35, 1618-22	5.5	3
41	Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. *Psychiatry Research*, **2011**, 185, 20-6	9.9	39
40	Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. *Journal of Affective Disorders*, **2011**, 133, 150-7	6.6	16
39	No significant association between SIRT1 gene and methamphetamine-induced psychosis in the Japanese population. *Human Psychopharmacology*, **2011**, 26, 445-50	2.3	6
38	Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence. *Current Neuropharmacology*, **2011**, 9, 129-32	7.6	4
37	No Association Between GRM3 and Japanese Methamphetamine-Induced Psychosis. *Current Neuropharmacology*, **2011**, 9, 160-2	7.6	1
36	Lack of association between prokineticin 2 gene and Japanese methamphetamine dependence. *Current Neuropharmacology*, **2011**, 9, 133-6	7.6	2
35	Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese. *Current Neuropharmacology*, **2011**, 9, 155-9	7.6	2
34	Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. *Neuropsychobiology*, **2010**, 61, 57-63	4	23
33	Copy number variation in schizophrenia in the Japanese population. *Biological Psychiatry*, **2010**, 67, 283-6	7.9	95
32	Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. *Neuroscience Research*, **2010**, 66, 340-4	2.9	21
31	Serotonin 6 receptor gene and mood disorders: case-control study and meta-analysis. *Neuroscience Research*, **2010**, 67, 250-5	2.9	13
30	Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 639-44	5.5	23

29	PROKR2 is associated with methamphetamine dependence in the Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 1033-6	5.5	14
28	Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. *Neuropharmacology*, **2010**, 58, 452-6	5.5	29
27	Association analysis of SIGMAR1 with major depressive disorder and SSRI response. *Neuropharmacology*, **2010**, 58, 1168-73	5.5	25
26	Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. *Psychopharmacology*, **2010**, 209, 185-90	4.7	6
25	Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population. *NeuroMolecular Medicine*, **2010**, 12, 78-85	4.6	11
24	HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. *NeuroMolecular Medicine*, **2010**, 12, 237-42	4.6	45
23	Lack of association between MAGEL2 and schizophrenia and mood disorders in the Japanese population. *NeuroMolecular Medicine*, **2010**, 12, 285-91	4.6	2
22	SIRT1 gene is associated with major depressive disorder in the Japanese population. *Journal of Affective Disorders*, **2010**, 126, 167-73	6.6	87
21	Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. *Human Psychopharmacology*, **2010**, 25, 481-6	2.3	16
20	Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. *Neuropsychobiology*, **2009**, 59, 234-8	4	10
19	Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. *Journal of Human Genetics*, **2009**, 54, 629-33	4.3	53
18	Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. *European Archives of Psychiatry and Clinical Neuroscience*, **2009**, 259, 293-7	5.1	71
17	CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. *NeuroMolecular Medicine*, **2009**, 11, 53-7	4.6	41
16	Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. *NeuroMolecular Medicine*, **2009**, 11, 114-22	4.6	34
15	No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. *NeuroMolecular Medicine*, **2009**, 11, 123-7	4.6	19
14	Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 875-9	5.5	29
13	A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 895-8	5.5	17
12	Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. *Neuroscience Research*, **2009**, 64, 231-4	2.9	30

11	Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. *Neuroscience Research*, **2009**, 65, 259-62	2.9	41
10	Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. *Schizophrenia Research*, **2009**, 110, 140-8	3.6	103
9	BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. *Schizophrenia Research*, **2009**, 112, 72-9	3.6	45
8	Association analysis of functional polymorphism in estrogen receptor alpha gene with schizophrenia and mood disorders in the Japanese population. *Psychiatric Genetics*, **2009**, 19, 217-8	2.9	7
7	Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. *Neuroscience Research*, **2008**, 62, 211-5	2.9	57
6	Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population. *Journal of Neural Transmission*, **2008**, 115, 1457-61	4.3	10
5	No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2008**, 147B, 531-4	3.5	13
4	Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 63-9	6.5	16
3	Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 70-82	6.5	14
2	Prostate apoptosis response 4 gene is not associated with methamphetamine-use disorder in the Japanese population. *Annals of the New York Academy of Sciences*, **2008**, 1139, 83-8	6.5	5
1	Clinical Investigation of Accumulation Process of 99mTc-HMDP and -MDP in Bone. *Radioisotopes*, **2000**, 49, 292-297	0.1	0